45 related articles for article (PubMed ID: 2519238)
21. [Systemic neoadjuvant chemotherapy in locally advanced gastric carcinoma: phase II study with 5-fluorouracil, epirubicin and etoposide].
Catania G; Puleo C; Catalano F; Altadonna V; Scilletta S; Migliore M; Iuppa A; Cardì F
Chir Ital; 2000; 52(4):385-91. PubMed ID: 11190529
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601.
Findlay M; Storey D; Gebski V; Hargreaves C; Cullingford G; Boyer M; Trotter J; Archer S; Davidson A; Johnston P; Yuen J; Dhillon H; Della-Fiorentina S; Richardson G; Truskett P; Goldstein D;
ANZ J Surg; 2007 Apr; 77(4):247-52. PubMed ID: 17388828
[TBL] [Abstract][Full Text] [Related]
23. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
[TBL] [Abstract][Full Text] [Related]
24. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
25. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
26. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
[TBL] [Abstract][Full Text] [Related]
27. Dose escalation and split course of 4-epidoxorubicin in combination chemotherapy (FEM II) of advanced gastric carcinoma. A phase-II trail of the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'.
Queisser W; Flechtner H; Heim ME; Kabelitz K; Massner B; Edler L
Onkologie; 1989 Oct; 12(5):202-6. PubMed ID: 2511533
[TBL] [Abstract][Full Text] [Related]
28. 5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
Flechtner H; Queisser W; Heim ME; Henss H; Arnold H; Fritze D; Herrmann R; Fritsch H; Fritz M; Trux FA
Onkologie; 1987 Apr; 10(2):67-71. PubMed ID: 3108738
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II). From the Chemotherapy of Gastrointestinal Tumors Group].
Verhees S; Flechtner H; Queisser W; Heim ME; Fritz M; Trux F; Edler L
Onkologie; 1990 Feb; 13(1):50-2. PubMed ID: 1692400
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach.
Gebbia V; Testa A; Valenza R; Latteri M; Bajardi G; Mastrandrea G; Cipolla C; Pischedda G; Curto G; Cannata G
J Chemother; 1994 Apr; 6(2):147-51. PubMed ID: 7521395
[TBL] [Abstract][Full Text] [Related]
31. Use of 5-fluorouracil, epirubicin and mitomycin C (FEM) as adjuvant therapy in node-positive, radically-resected gastric cancer patients: survey of a general hospital experience.
Caffo O; Ambrosini G; Amichetti M; Brugnara S; Graiff C; Robbiati SF; Galligioni E
Oncol Rep; 1998; 5(6):1465-9. PubMed ID: 9769389
[TBL] [Abstract][Full Text] [Related]
32. [GASTRIC CANCER IN PATIENTS YOUNGER THAN FORTY YEARS OLD.HOSPITAL LOAYZA EXPERIENCE BETWEEN 1991 - 1998].
Rivera F; Nago A; Bussalleu A; Medina R; Lizama O; Loayza G
Rev Gastroenterol Peru; 2000; 20(3):247-260. PubMed ID: 12140586
[TBL] [Abstract][Full Text] [Related]
33. Effect of combination of 5-fluorouracil, epirubicin and mitomycin C (FEM) on advanced gastric carcinoma.
Itoh T; Sakata Y; Tamura Y; Furukohori N; Saitoh S; Suzuki H; Tsushima K; Munakata A; Yoshida Y; Takagi S
Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1551-6. PubMed ID: 2509606
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of FEM (5-fluorouracil, epirubicin, mitomycin C) therapy for resected advanced gastric cancer. Ehime Gastric Cancer Study Meeting].
Kurita A; Takashima S; Sakakihara Y; Tsunekawa K; Matsuzaka T
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2319-24. PubMed ID: 8259845
[TBL] [Abstract][Full Text] [Related]
36. Clinical profile of carcinoma stomach at a tertiary care hospital in south India.
Sambasivaiah K; Ibrarullah M; Reddy MK; Reddy PV; Wagholikar G; Jaiman S; Reddy DG; Sarma KV; Hegde GN
Trop Gastroenterol; 2004; 25(1):21-6. PubMed ID: 15303466
[TBL] [Abstract][Full Text] [Related]
37. [Combined chemotherapy with the FEM protocol in advanced gastric cancer].
Vallejos C; Payet C; Nuñez J; Montalbetti J; Solidoro A; Salazar F; Sánchez J; Celis J; Casanova L; Otero J
Rev Gastroenterol Peru; 1989; 9(2):91-4. PubMed ID: 2519238
[TBL] [Abstract][Full Text] [Related]
38. The clinical impact of FEM regimen (5-fluorouracil, 4-epidoxorubicin and mitomycin-C) in advanced gastric cancer patients.
Cascinu S; Latini L; Fedeli A; Giordani P; Antognoli S; Catalano G; Cellerino R
Anticancer Res; 1995; 15(6B):2781-3. PubMed ID: 8669864
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
